| Name | Clopidogrel hydrogen sulfate |
| Description | Clopidogrel hydrogen sulfate ((S)-(+)-Clopidogrel bisulfate) , a selective, high-affinity P2Y12 receptor antagonist, suppressess fibrinogen binding to platelets and platelet adhesion and aggregation. |
| In vitro | In a rat model of ulcer margins, daily administration of Clopidogrel (2 mg and 10 mg/kg) significantly reduced the proliferation of gastric epithelial cells induced by ulcers, as well as the expression of the EGF receptor and phosphorylated extracellular signal-regulated kinase. In rats with congestive heart failure, Clopidogrel enhanced the phosphorylation of AKT and eNOS, thereby improving vascular endothelial function and the bioavailability of nitric oxide. |
| In vivo | In RGM-1 cells, Clopidogrel (1 μM) inhibits the epidermal growth factor-induced activation of epidermal growth factor receptor, PERK expression, and cellular proliferation. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility Information | DMSO : 55 mg/mL (130.98 mM)
|
| Keywords | Inhibitor | Antiplatelet | Clopidogrel hydrogen | Clopidogrel Bisulfate | P2Y Receptor | platelet | Clopidogrel hydrogen sulfate | CYP2C19 | CYPs | clot | antithrombotic | Clopidogrel hydrogen Sulfate | inhibit | aggregation | Cytochrome P450 | blood | CYP2B6 |
| Inhibitors Related | Tebuconazole | 1-Ethynylnaphthalene | Apigenin | Gemfibrozil | Fenofibrate | 1-Aminobenzotriazole | Uridine-5'-diphosphate disodium salt | Naringin | Naringenin | Tauroursodeoxycholate |
| Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | EMA Approved Drug Library | Anti-Cancer Clinical Compound Library | Drug Repurposing Compound Library | Anti-Cancer Approved Drug Library | FDA-Approved Drug Library | Anti-Aging Compound Library | Bioactive Compounds Library Max | GPCR Compound Library |
United States
